July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Minimizing Recurrences of Ocular Inflammation and Need for Adjunctive Treatment of Non-infectious Posterior Uveitis (NIPU) during the 2 Years Following Treatment with a Single 0.18 mg Fluocinolone Acetonide Intravitreal Insert (FAi)
Author Affiliations & Notes
  • Quan Dong Nguyen
    Byers Eye Institute, Stanford University, Palo Alto, California, United States
  • Keyur Patel
    EyePoint Pharmaceuticals, Boston, Massachusetts, United States
  • Dario A Paggiarino
    EyePoint Pharmaceuticals, Boston, Massachusetts, United States
  • EyePoint FAi Investigators
    EyePoint Pharmaceuticals, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Quan Nguyen, EyePoint (F), Genentech (F), Gilead (F), Regeneron (F), Santen (F); Keyur Patel, EyePoint (E); Dario Paggiarino, EyePoint (E); EyePoint FAi Investigators, EyePoint (F)
  • Footnotes
    Support  pSivida Corporation; Research to Prevent Blindness, Inc (unrestricted grant to the Byers Eye Institute at Stanford; National Eye Institute (P30-EY026877 Core Grant to the Byers Eye Institute at Stanford)
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 3513. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Quan Dong Nguyen, Keyur Patel, Dario A Paggiarino, EyePoint FAi Investigators; Minimizing Recurrences of Ocular Inflammation and Need for Adjunctive Treatment of Non-infectious Posterior Uveitis (NIPU) during the 2 Years Following Treatment with a Single 0.18 mg Fluocinolone Acetonide Intravitreal Insert (FAi). Invest. Ophthalmol. Vis. Sci. 2019;60(9):3513.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Cumulative damage from repeated inflammatory episodes has been associated with significant visual morbidity in patients with NIPU. The number of recurrences of uveitis over 2 years was compared among eyes treated with the FAi and those treated with a sham injection in a prospective, randomized, double-masked phase 3 clinical trial.

Methods : Subjects with a > 1-year history of recurrent NIPU, who had experienced at least 2 separate recurrences requiring ≥ 3 months of systemic therapy or ≥ 2 intra- or periocular steroid injections, were randomized to treatment with FAi or sham. Cumulative recurrence of uveitis, defined as 1) ≥ +2 increase in vitreous haze; or 2) ≥ 15-letter loss of VA; or imputed in case of rescue treatment for ocular inflammation or missing data, as well as the nature of the rescue treatments, was compared through 2 years of an on-going 3-year clinical trial.

Results : 129 subjects (87 FAi, 42 sham) with NIPU were enrolled. During the first 24M of the study, the recurrence rate in FAi randomized eyes (41/87, 47%) was significantly lower than in sham eyes (39/42, 93%), p<0.001. A total of 81 recurrences were reported in FAi treated eyes (0.9±1.7/eye) versus 126 recurrences in sham treated eyes (3.0±2.3/eye). Multiple (>1) recurrences were observed in 18% (16/87) of the FAi treated eyes and 67% (28/42) of the sham treated eyes. Intra/peri-ocular injections were used to control inflammation in 16% (14/87) and 67% (28/42) of FAi and sham eyes respectively while systemic treatments were given to 28% (24/87) and 50% (21/42) of patients. Adverse events included elevated IOP requiring medical treatment (41% FAi vs 33% sham) and cataract extractions (64% FAi vs 14% sham).

Conclusions : A single FAi treatment resulted in a reduced rate of uveitis recurrence over 2 years as well as cumulative total recurrent episodes and consequent reduction in exposure to adjunctive anti-inflammatory medications.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×